...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Due Dilligence
Epigenetic Therapeutic Targets Summit, 7/15/2021: Clinical Development of the BET Bromodomain Inhibitor ZEN-3694
Posted by:
BearDownAZ
on
Jul 22, 2021 09:56AM
Triple Negative Breast Cancer Drug Development Digital Summit 4/29/2021
Posted by:
BearDownAZ
on
Jun 24, 2021 04:13PM
Zenith Epigenetics Links
BET inhibitors: a novel epigenetic approach
A review focused on pre-clinical and early clinical results of BET inhibitors for treating oncology indications (access/subscription may be required)
Posted by:
BearDownAZ
on
Oct 09, 2017 02:25PM
Drug Discovery Targeting Bromodomain-Containing Protein 4
A chemical structure focused review on BRD4 BET inhibitor drug discovery and development
Posted by:
BearDownAZ
on
Oct 09, 2017 02:23PM
Zenith Presentations and Publications
Also see NCBI PubMed list here: https://www.ncbi.nlm.nih.gov/pubmed/?term=%22Zenith+epigenetics%22
Posted by:
BearDownAZ
on
Sep 27, 2017 01:48PM
Alberta Epigenetics Network Annual Summit 2016 – Abstract 1
Posted by:
BearDownAZ
on
Sep 27, 2017 08:24AM
Alberta Epigenetics Network Annual Summit 2016 – Abstract 2
Posted by:
BearDownAZ
on
Sep 27, 2017 08:23AM